IL325762A - נוגדן אנטי- cd7 אנושי - Google Patents
נוגדן אנטי- cd7 אנושיInfo
- Publication number
- IL325762A IL325762A IL325762A IL32576226A IL325762A IL 325762 A IL325762 A IL 325762A IL 325762 A IL325762 A IL 325762A IL 32576226 A IL32576226 A IL 32576226A IL 325762 A IL325762 A IL 325762A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- humanized anti
- humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23185199 | 2023-07-13 | ||
| PCT/EP2024/068866 WO2025012080A1 (en) | 2023-07-13 | 2024-07-04 | Humanized anti-cd7 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325762A true IL325762A (he) | 2026-03-01 |
Family
ID=87280574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325762A IL325762A (he) | 2023-07-13 | 2024-07-04 | נוגדן אנטי- cd7 אנושי |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4743490A1 (he) |
| KR (1) | KR20260042196A (he) |
| CN (1) | CN121729431A (he) |
| AU (1) | AU2024296212A1 (he) |
| IL (1) | IL325762A (he) |
| MX (1) | MX2026000497A (he) |
| WO (1) | WO2025012080A1 (he) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| AU2002361390A1 (en) | 2001-12-14 | 2003-06-30 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Anti-cd7 immunotoxin as fusion protein |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| KR102117202B1 (ko) | 2011-08-16 | 2020-06-01 | 모르포시스 아게 | 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법 |
| KR101521224B1 (ko) * | 2012-12-20 | 2015-05-19 | 한양대학교 산학협력단 | T 세포 특이적인 인간화 단일조각항체 전달체 |
| TW202017612A (zh) | 2018-11-08 | 2020-05-16 | 小林照男 | 濃縮氧氣增壓裝置及濃縮氧氣增壓方法 |
| GB201905552D0 (en) | 2019-04-18 | 2019-06-05 | Kymab Ltd | Antagonists |
| CN112300282A (zh) | 2020-11-03 | 2021-02-02 | 南京北恒生物科技有限公司 | 靶向cd7的人源化抗体及其用途 |
| US20250222026A1 (en) | 2021-06-08 | 2025-07-10 | Beijing Meikang Geno-Immune Biotechnology Co., Ltd. | Cd7-based humanized chimeric antigen receptor and use thereof |
| CN115991776B (zh) | 2022-10-26 | 2023-08-01 | 上海驯鹿生物技术有限公司 | 一种靶向cd7的全人源抗体及其应用 |
-
2024
- 2024-07-04 IL IL325762A patent/IL325762A/he unknown
- 2024-07-04 CN CN202480053217.0A patent/CN121729431A/zh active Pending
- 2024-07-04 EP EP24740106.0A patent/EP4743490A1/en active Pending
- 2024-07-04 WO PCT/EP2024/068866 patent/WO2025012080A1/en not_active Ceased
- 2024-07-04 AU AU2024296212A patent/AU2024296212A1/en active Pending
- 2024-07-04 KR KR1020267003927A patent/KR20260042196A/ko active Pending
-
2026
- 2026-01-13 MX MX2026000497A patent/MX2026000497A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024296212A1 (en) | 2026-01-22 |
| MX2026000497A (es) | 2026-03-02 |
| KR20260042196A (ko) | 2026-03-30 |
| EP4743490A1 (en) | 2026-05-20 |
| CN121729431A (zh) | 2026-03-24 |
| WO2025012080A1 (en) | 2025-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202205226B (en) | Ri-labeled humanized antibody | |
| EP4219554A4 (en) | HUMANIZED CD7-TARGETED ANTIBODY AND USE THEREOF | |
| GB202305426D0 (en) | Antibodies | |
| CA3265092A1 (en) | Humanized Anti-Nectin-4 Antibodies | |
| GB202309981D0 (en) | Antibody | |
| CA3297565A1 (en) | Humanized anti-cd7 antibody | |
| AU2024296212A1 (en) | Humanized anti-cd7 antibody | |
| GB202304512D0 (en) | Antibodies | |
| GB202217924D0 (en) | Antibodies | |
| EP4313112A4 (en) | MAB107 HUMANIZED | |
| GB202204159D0 (en) | Antibodies | |
| GB202313544D0 (en) | monoclonal antibody | |
| GB202306125D0 (en) | Monoclonal antibody | |
| CA3297257A1 (en) | Humanized 40h3 antibody | |
| AU2024296940A1 (en) | Humanized 40h3 antibody | |
| GB202316821D0 (en) | Anti-ifn-gamma antibodies | |
| GB202319122D0 (en) | Antibody | |
| GB202319149D0 (en) | Antibody | |
| IL315568A (he) | נוגדנים zip12 | |
| GB202206195D0 (en) | Antibody | |
| HK40102583A (en) | Humanized antibodies against irhom2 | |
| IL312392A (he) | נוגדנים מונוקלונאליים מנטרלים נגד סרבקווירוסים | |
| GB202504529D0 (en) | Antibody | |
| GB202417731D0 (en) | ZIP12 Antibody | |
| GB202408492D0 (en) | Anti-alpha-synuclein antibody |